Sarfez Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sarfez Pharmaceuticals is a private, commercial-stage biotech founded in 2018, headquartered in San Diego, California. The company has successfully brought its lead product, SOAANZ® (a novel slow-release formulation of torsemide), to market for edema in heart failure and kidney disease patients. Its business model is centered on therapeutics, and it is currently in the revenue-generating stage, leveraging digital discount platforms like GoodRx for patient access. The company faces regulatory scrutiny, as evidenced by a recent FDA corrective communication, and operates in a competitive generic drug landscape.

CardiovascularNephrology

Technology Platform

Novel slow-release (SR) formulation technology for torsemide, a loop diuretic, aimed at providing sustained diuresis with once-daily dosing.

Opportunities

Large and growing patient populations with heart failure and chronic kidney disease provide a significant addressable market.

A successful slow-release formulation could offer improved adherence and more consistent symptom control compared to immediate-release generics, creating a niche for branded therapy.

Strategic use of discount platforms like GoodRx can facilitate initial patient access and trial.

Risk Factors

The company recently faced an FDA-mandated corrective communication for misleading promotional claims, creating regulatory and reputational risk.

It competes directly against low-cost, entrenched generic loop diuretics, making market penetration challenging.

The company's entire value is concentrated in a single commercial product, with no disclosed pipeline, creating high dependency risk.

Competitive Landscape

SOAANZ® operates in the highly competitive loop diuretic market, dominated by inexpensive generic furosemide and immediate-release torsemide. Other branded diuretics exist but are not direct SR competitors. Success depends on convincing prescribers of a clinically meaningful benefit over generics to justify a branded price, a significant challenge in cost-conscious healthcare systems.

More companies in United States →